Roth MKM Maintains Buy on Evogene, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Brian Wright maintains a 'Buy' rating on Evogene (NASDAQ:EVGN) and has raised the price target from $1 to $6.
July 21, 2023 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst has maintained a 'Buy' rating on Evogene and raised the price target from $1 to $6, which could positively impact the stock's price.
The 'Buy' rating maintained by Roth MKM indicates a positive outlook for Evogene. The significant increase in the price target from $1 to $6 suggests that the analyst sees substantial upside potential for the stock, which could drive its price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100